FDA Update

Alberto Gutierrez, Ph.D.

Organizational Change - Center

- Jeff Shuren, MD, JD
- □ Nation wide search in progress for
 - New Deputy for Science
 - New Deputy for Policy

Agency Initiatives

- □ Protecting Public Health
 - Quick compliance actions
 - Pro-actively manage public health issues
 - □ Glucose Meters
 - Personalized Medicine
 - Emerging Infectious Diseases and Biodefense

Agency Initiatives

- □ Transparency
 - Twitter
 - Public Meetings
 - YouTube
 - Public Score Cards

Center Initiatives

- □ Ambitious Strategic Plan
- \square Program review 510(k)
 - Internal Review
 - IOM Review

Center Initiatives – Public Meetings

- □ Incorporation of New Science Into Regulatory Decision making Program review – 510(k) – Feb 9
- □ Strengthening the Center for Devices and Radiological Health's 510(k)
 Review Process Feb 18
- □ Blood Glucose Meters March 16-17

Guidances

- □ Antimicrobial Susceptibility Tests
- Detection or Detection and Differentiation of HPV
- □ H1N1 EUA

Guidances – Special Controls

- Respiratory Panel
 - Influenza A Virus Subtypes
 - Human Metapneumovirus (hMPV)
 - Respiratory Viral Panel Multiplex
- Cardiac Allograft Gene Expression Profiling Tests

Notable New Approvals/Clearances

- □ Clearances
 - OVA1

Emergency Use Authorizations

- □ 14 EUAs
 - CDC, DoD, Manufacturers, and CLIA laboratories
 - 1 Moderate Complexity
 - Waiver on the horizon?

Notable Meetings

- Advisory Panel Meeting on Digital Pathology
- □ FDA-IDSA Respiratory Tract Infections Workshop

Postmarket Actions – Class I Recalls

- □ Hettich Centrifuges with 2050 and 2076
 Plastic Rotors 11/21/09
- □ Pointe Scientific, Inc., Liquid Glucose Hexokinase Reagent – 10/19/09
- □ Biosite Incorporated, Triage Cardiac Panel 4/27/09

Postmarket Actions – Public Health Notification

□ Potentially Fatal Errors with GDH-PQQ*
 Glucose Monitoring Technology – 8/13/09

Postmarket Actions – Warning Letters

■ Millipore Corp. Marketing unauthorized or unapproved H1N1 diagnostic products

CLIA Waivers

- □ 401 categorizations
 - 163 by regulation glucose meters, urine dipsticks, FOB, urine pregnancy
 - 151 by OTC
 drugs of abuse, cholesterol, HDL, triglyceride
 - 87 by request
 Previously waived by studies but now relabeled or change in name/ distributor
 - 2 devices (31 categorizations) waived and 1 denied waiver

CLIA Waivers

□ Performance

FDA Decision	FDA Days	MFG Days	Total
APPR – Approved	233	0	233
APPR – Approved	204	64	268
Denied	320	38	744